ArticleThe Lancet. Haematology2022

Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.

Feng Xue et al.PubMed ↗Publisher ↗

No numbers read from the abstract.